Skip to main content
Peter Oppelt, MD, Oncology, Saint Louis, MO

PeterJohnOppeltMD

Oncology Saint Louis, MO

Hematology Oncology Fellow

Dr. Oppelt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Oppelt's full profile

Already have an account?

  • Office

    4921 Parkview Pl
    # Dv
    Saint Louis, MO 63110
    Phone+1 800-647-2098
    Fax+1 314-362-3192

Education & Training

  • Case Western Reserve University/University Hospitals Cleveland Medical Center
    Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
  • Case Western Reserve University/University Hospitals Cleveland Medical Center
    Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2008 - 2012
  • University of Missouri-Columbia School of Medicine
    University of Missouri-Columbia School of MedicineClass of 2008

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2020 - 2026
  • MO State Medical License
    MO State Medical License 2015 - 2025
  • OH State Medical License
    OH State Medical License 2008 - 2016

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Outcomes of Patients with Single-Node Metastasis of Human Papillomavirus–Related Oropharyngeal Cancer Treated with Transoral Surgery  
    Peter Oppelt, Kevin Palka, JAMA Otolaryngology–Head & Neck Surgery

Press Mentions

  • Safety and Efficacy of Zimberelimab (AB122) in Combination with Domvanalimab (AB154) and Etrumadenant (AB928) in Patients with Previously Treated Non-Small Cell Lung Cancer
    Safety and Efficacy of Zimberelimab (AB122) in Combination with Domvanalimab (AB154) and Etrumadenant (AB928) in Patients with Previously Treated Non-Small Cell Lung CancerMarch 10th, 2021